Bioengine

Executive Summary

Bioengine is a Shanghai-based synthetic biology company founded in 2014, leveraging computational design, DNA synthesis, and high-throughput screening to engineer novel biologics. The company focuses on sustainable biomanufacturing of enzymes, proteins, and microbial strains for pharmaceutical, chemical, and material applications. With a platform-stage business model and 50-200 employees, Bioengine aims to optimize biological production processes, reducing costs and environmental impact. Despite limited public information, its technology positions it in the growing synthetic biology market, particularly in China's biotech sector. The company's private status and lack of disclosed funding or valuation suggest it may be in an early commercial or growth phase, with potential for partnership or scale-up opportunities.

Upcoming Catalysts (preview)

• Q4 2026Series B or C funding round closure70% success
• H2 2026Licensing or partnership deal with a major pharmaceutical company50% success
• Q1 2027Launch of a commercial biomanufacturing product (e.g., enzyme or protein)40% success